Cogent Biosciences, Inc.
COGT · XNASCIK 1622229fmd_1PB6EB96XV9BBF6MXJ6FX6N24RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 10 | 22 | 8 | – | – | – | – | – |
| Research and development | 30 | 38 | 44 | 26 | 56 | 122 | 174 | 233 | 270 |
| Operating income | (26) | (36) | (32) | (82) | (76) | (148) | (208) | (276) | (333) |
| Interest expense | – | – | – | – | – | – | – | – | 3 |
| Interest and investment income | 0 | 1 | 0 | 0 | 0 | 4 | 13 | 18 | 15 |
| Other non-operating income (expense) | 1 | 1 | 0 | 7 | 3 | 8 | 16 | 20 | 4 |
| Income tax expense | – | – | – | – | – | – | – | – | 0 |
| Net income | (25) | (35) | (32) | (75) | (72) | (140) | (192) | (256) | (329) |
| Net income to common shareholders | (26) | (35) | (32) | (179) | (72) | (140) | (192) | – | – |